SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb Says KarXT Improved Alzheimer's Hallucinations and Delusions

Bristol Myers Squibb said preliminary data from a Phase 3 study showed improvements in hallucinations, delusions and overall disease severity among Alzheimer's patients.

BMY

Related stories